Finessing oncology targets can be both tricky and challenging. Does changing the modality help?
Sometimes we learn more from failure than we do from success
A number of new developments to consider in the KRAS niche
With SITC fast coming up this week, immunotherapies in all sorts of shapes and guises are very much…
Update on the various runners and riders in the TIGIT niche
A look at the sheer breadth and depth of bispecific approaches from a myriad of different biotechs
SITC 2021 Preview
